Suppr超能文献

甲状腺激素受体β在间变性甲状腺癌中诱导肿瘤抑制程序。

Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer.

机构信息

Department of Pharmacology, Larner College of Medicine, Burlington, Vermont.

University of Vermont Cancer Center, Burlington, Vermont.

出版信息

Mol Cancer Res. 2020 Oct;18(10):1443-1452. doi: 10.1158/1541-7786.MCR-20-0282. Epub 2020 Jun 17.

Abstract

The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is noted in thyroid, breast, and other solid tumors and is correlated with more aggressive disease. Restoration of TRβ levels decreased tumor growth supporting the concept that TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem cell populations and induces cell death in a T-dependent manner. Transcriptomic analysis of SW-TRβ cells via RNA sequencing revealed distinctive expression patterns induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of thyroid differentiation markers, and promoted proapoptotic pathways. Our results further revealed the JAK1-STAT1 pathway as a novel, T-mediated, antitumorigenic pathway that can be activated in additional ATC lines. These findings elucidate a TRβ-driven tumor suppression transcriptomic signature, highlight unexplored therapeutic options for ATC, and support TRβ activation as a promising therapeutic option in cancers. IMPLICATIONS: TRβ-T induced a less aggressive phenotype and tumor suppression program in anaplastic thyroid cancer cells revealing new potential therapeutic targets.

摘要

甲状腺激素受体β(TRβ)是细胞生长和分化的关键调节剂,在癌症中经常失调。TRβ的表达减少在甲状腺、乳腺和其他实体瘤中被注意到,并且与更具侵袭性的疾病相关。TRβ水平的恢复降低了肿瘤生长,支持了 TRβ 可以作为肿瘤抑制因子的概念。然而,TRβ 的肿瘤抑制转录组尚未得到很好的描绘,并且在侵袭性间变性甲状腺癌(ATC)中 TRβ 的影响尚不清楚。在这里,我们建立了在人 ATC 细胞系 SW1736(SW-TRβ)中恢复 TRβ 表达可降低侵袭性表型、减少癌症干细胞群体并以 T 依赖性方式诱导细胞死亡。通过 RNA 测序对 SW-TRβ 细胞进行的转录组分析揭示了配体结合的 TRβ 诱导的独特表达模式,并揭示了新的分子信号通路。值得注意的是,配体结合的 TRβ 抑制了 PI3K/AKT 通路中的多个节点,诱导甲状腺分化标志物的表达,并促进促凋亡途径。我们的研究结果进一步揭示了 JAK1-STAT1 通路是一种新的、T 介导的抗肿瘤通路,可在其他 ATC 系中被激活。这些发现阐明了 TRβ 驱动的肿瘤抑制转录组特征,突出了 ATC 未探索的治疗选择,并支持 TRβ 激活作为癌症的有前途的治疗选择。意义:TRβ-T 在间变性甲状腺癌细胞中诱导出侵袭性较低的表型和肿瘤抑制程序,揭示了新的潜在治疗靶点。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验